ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
Home » Archive by Category

Syndication

Manufacturing Technician – Pharmatek Laboratories, Inc. – San Diego, CA

February 2, 2016 – 4:21 pm

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Indeed – 02 Feb 2016 23:21:10 GMT
– View all San Diego jobs

Orexigen Therapeutics to Speak at Upcoming Investor Conferences

February 2, 2016 – 2:15 pm

SAN DIEGO, Feb. 2, 2016 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:

BIO CEO & Investor Conference

Date:

Tuesday, February 9, 2016

Time:

3:00 p.m. Eastern Time

Location:

New York, NY

 

Leerink Swann Global Healthcare Conference

Date:

Thursday, February 11, 2016

Time:

10:45 a.m. Eastern Time

Location:

New York, NY

To listen to live webcasts of each presentation or to a replay of the discussions, please visit the Investors section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Julie Normart

VP, Corporate Communications and Business Development

BrewLife

(858) 875-8629

(415) 946-1087

mstilwell@orexigen.com

jnormart@brewlife.com

 

SOURCE Orexigen Therapeutics, Inc.

Research Scientist, Statistical Genetics (Carlsbad)

February 2, 2016 – 8:54 am

Predictive Biology, Inc. is seeking a full time Research Scientist, Statistical Genetics. We have developed a high throughput in vitro genetics platform for QTL screens of compound effects in many different cell systems. Using panels of several hundr […

Research Scientist, Statistical Genetics (Carlsbad)

February 2, 2016 – 8:54 am

Predictive Biology, Inc. is seeking a full time Research Scientist, Statistical Genetics. We have developed a high throughput in vitro genetics platform for QTL screens of compound effects in many different cell systems. Using panels of several hundr […

Symic to Present at the 18th Annual BIO CEO & Investor Conference

February 2, 2016 – 8:00 am

SAN FRANCISCO, Feb. 2, 2016 /PRNewswire/ — Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference in New York.

Conference details are as follows:

Date: Tuesday, Feb. 9, 2016

Time: 11:45 a.m. EST

Location: The Waldorf Astoria New York

About Symic

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic’s proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic’s lead compound, SB-030, is currently under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury. In addition, Symic’s osteoarthritis drug candidate, SB-061, is poised to enter the clinic in the next few months.

Symic is based in San Francisco. For additional information, please visit the company’s website at http://www.symic.bio or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

 

SOURCE Symic

Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016

February 2, 2016 – 6:30 am

SAN JOSE, Feb. 2, 2016 /PRNewswire/ — Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the Company will present at BIO CEO & Investor Conference 2016, taking place in New York February 8-9, 2016.

Vu Truong, Ph.D., Founder and Chief Executive Officer of Aridis Pharmaceuticals, will provide an overview of the Company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:  BIO CEO & Investor Conference 2016
Date: Monday, February 8, 2016
Time: 08:45 am (Eastern Time)
Location:  Waldorf Astoria; Park North Room

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX® to produce novel infectious disease focused therapies.  Aridis’ product pipeline includes AR-101 (Aerumab®) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin®) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin®, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin®, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.  Such forward-looking statements include statements relating to the therapeutic applications of Aerumab® (AR-101), Salvecin® (AR-301), Aerucin®, Panaecin®, AR-401, AR-201, Aridis’ proprietary formulation and delivery technologies, about Aridis’ strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis’ research and clinical studies and its ability to obtain additional financing.  These forward-looking statements represent Aridis’ judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc. 
Tirth Patel (investors)
tpatel@tiberend.com 
(212) 375-2681

Andrew Mielach (media)
amielach@tiberend.com 
(212) 375-2694

SOURCE Aridis Pharmaceuticals, Inc.

Mast Therapeutics To Present At 2016 BIO CEO & Investor Conference On February 8th

February 2, 2016 – 6:00 am

SAN DIEGO, Feb. 2, 2016 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel clinical-stage therapies for sickle cell disease and heart failure today announced that the Company’s Chief Executive Officer, Brian M. Culley, will present at the 2016 BIO CEO & Investor Conference on Monday, February 8, 2016 at 2:00 p.m. Eastern time in the Conrad Salon at the Waldorf Astoria hotel in New York.

Interested parties can access a live audio webcast on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes.  The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulization.

Vepoloxamer is an investigational new drug being tested in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure.  AIR001 is an investigational new drug in Phase 2a clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.  

Logo – http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 

SOURCE Mast Therapeutics, Inc.

Biotech Tech Assistant (Mira Mesa, San Diego)

February 1, 2016 – 8:03 pm

We are currently looking for a Lab Tech Assistant. It is a full-time job, afternoon shift, start from entry level, salary from $ 10 /hour or depend on experience (DOE).
Required to have basic biology knowledge.
Major duties include, lab clean and m […

Sr Software Engineer – Illumina, Inc. – San Diego, CA

February 1, 2016 – 4:45 pm

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 01 Feb 2016 23:45:00 GMT
– View all San Diego jobs

Bioinformatics Scientist 2 – Illumina, Inc. – San Diego, CA

February 1, 2016 – 4:45 pm

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. All About Us….
From Illumina, Inc. – 01 Feb 2016 23:45:00 GMT
– View all San Diego jobs